Supplementary file

Figure S1

Table 1 Raw Relative fluorescence unit (RFU) values of Alamar blue cell viability assay

	Relative fluorescence unit (RFU) - background					
	Bevacizumab (mg/ml)			Bevacizumab-awwb (mg/ml)		
	control	0.313	0.625	control	0.313	0.625
N1	514811251	480338931	503326291	479957395	449112915	471663571
N2	508640211	513189011	504922163	531135635	505236915	524570931
N3	528058355	520548403	487655603	514811251	529907699	514811251
N4	504720622	557259507	529467891	508640211	504348179	502949107

Table 2 Percentage of cell viability (% to control) (calculated from table 1)

	Cell viability (% to control)					
	Bevacizumab (mg/ml)			Bevacizumab-awwb (mg/ml)		
	control	0.313	0.625	control	0.313	0.625
N1	100	93.3	97.77	100	93.57	98.27
N2	100	100.89	99.27	100	95.12	98.76
N3	100	98.58	92.35	100	102.93	102.00
N4	100	110.41	104.9	100	99.16	95.24

Supplementary figure S3

Full-length membrane blots used in all figures are shown. Blots were performed using a capillary electrophoresis (CE) –based Western blot system (Simple Western™, Protein Simple, Santa Clara, CA, USA). The CE - based Western blot images were assessed for protein expression using the WES system (Protein Simple). M; protein marker.



Supplementary file figure S2 Gating strategy for apoptosis analysis using Annexin V/PI staining. (A) ARPE-19 cells were gated based on forward scatter (FSC) versus side scatter (SSC) to define the main cell population. (B) The selected population was analyzed by Annexin V-FITC and propidium iodide (PI) staining to identify live cells, early apoptotic cells, and late apoptotic/necrotic cells.